EGFR and ovarian carcinoma: Additionally, its efficiency to target EGFR has been shown using the GE11 peptide-modified polymersomal doxorubicin, which has emerged as an advanced alternative to the current Lipo-Dox treatment in EGFR over-expressing ovarian cancers [34].